Impact of Donor Age on Three-Year Outcomes in Recipients of Extended Criteria Kidneys Treated with Belatacept vs Cyclosporine in BENEFIT-EXT Trial.

被引：0
|
作者：
Budde, K. [1 ]
Morales, J. [2 ]
Blancho, G. [3 ]
Muehlbacher, F. [4 ]
Lehner, F. [5 ]
Rice, K. [6 ]
Pupim, L.
Aigner, S.
Vincenti, F. [7 ]
机构：
[1] Charite, Berlin, Germany
[2] Hosp 12 Octubre Madrid, Madrid, Spain
[3] Univ Hosp Nantes, Nantes, France
[4] Med Univ Vienna, Vienna, Austria
[5] Hannover Med Sch, Hannover, Germany
[6] Baylor Univ, Med Ctr, Waco, TX 76798 USA
[7] Univ Calif San Francisco, San Francisco, CA USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2013年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：182 / 183
页数：2
相关论文
共 38 条
  • [31] Outcomes at 3-Years in EBV plus Recipients of Deceased Donor Kidneys From Two Randomized Trials (BENEFIT and BENEFIT EXT) Comparing Belatacept vs Cyclosporine
    Muehlbacher, F.
    Durrbach, A.
    Florman, S.
    Medina Pestana, J.
    Harler, M.
    Larsen, C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 455 - 455
  • [32] Efficacy and Safety Outcomes of Extended Criteria Donor Kidneys by Subtype: Subgroup Analysis of BENEFIT-EXT at 7 Years After Transplant
    Florman, S.
    Becker, T.
    Bresnahan, B.
    Chevaile-Ramos, A.
    Carvalho, D.
    Grannas, G.
    Muehlbacher, F.
    O'Connell, P. J.
    Meier-Kriesche, H. U.
    Larsen, C. P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 (01) : 180 - 190
  • [33] LONG-TERM SURVIVAL OUTCOMES IN BELATACEPT-TREATED VS. CYCLOSPORINE-TREATED PATIENTS: FINAL RESULTS FROM BENEFIT-EXT
    Durrbach, Antoine
    Medina, Pestana Jose
    Florman, Sander
    Del Carmen, Rial Maria
    Rostaing, Lionel
    Kuypers, Dirk
    Wekerle, Thomas
    Polinsky, Martin
    Meier-Kriesche, Herwig-Ulf
    Grinyo, Josep
    TRANSPLANT INTERNATIONAL, 2015, 28 : 81 - 81
  • [34] LONG-TERM SURVIVAL OUTCOMES IN BELATACEPT-TREATED VS. CYCLOSPORINE-TREATED PATIENTS: FINAL RESULTS FROM BENEFIT-EXT
    Durrbach, A.
    Bray, R.
    Gebel, H.
    Florman, S.
    Kuypers, D.
    Larsen, C. P.
    Pestana, J. M.
    del Carmen Rial, M.
    Rostaing, L.
    Wekerle, T.
    Meier-Kriesche, U.
    Polinsky, M.
    Townsend, R.
    Grinyo, J.
    TRANSPLANT INTERNATIONAL, 2015, 28 : 10 - 10
  • [35] Likelihood of Improving or Maintaining Renal Function in Recipients of Extended-Criteria Donor Kidneys over Five Years with Belatacept or CsA (BENEFIT-EXT Long-Term Extension Study)
    Grinyo, J.
    Vanrenterghem, Y.
    Durrbach, A.
    Rial, M.
    Charpentier, B.
    Matas, A.
    Lehner, F.
    Pupim, L.
    Coffey, M.
    Pestana, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 310 - 310
  • [36] Long-Term Survival Outcomes in Belatacept-Treated vs. Cyclosporine-Treated Patients: Final Results From BENEFIT-EXT
    Florman, S.
    Bray, R.
    Gebel, H.
    Kuypers, D.
    Larsen, C.
    Medina Pestana, J.
    Rial, M.
    Rostaing, L.
    Wekerle, T.
    Grannas, G.
    Meier-Kriesche, U.
    Polinsky, M.
    Townsend, R.
    Munier, S.
    Grinyo, J.
    Durrbach, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 : 45 - 45
  • [37] De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies
    Bray, R. A.
    Gebel, H. M.
    Townsend, R.
    Roberts, M. E.
    Polinsky, M.
    Yang, L.
    Meier-Kriesche, H. -U.
    Larsen, C. P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 (07) : 1783 - 1789
  • [38] OUTCOMES AT 3-YEARS IN EBV plus RECIPIENTS OF DECEASED DONOR KIDNEYS FROM TWO RANDOMIZED TRIALS (BENEFIT AND BENEFIT EXT) COMPARING BELATACEPT VERSUS CYCLOSPORINE
    Durrbach, A.
    Muehlbacher, F.
    Florman, S.
    Pestana, J. Medina
    Harler, M. B.
    Larsen, C.
    TRANSPLANT INTERNATIONAL, 2015, 28 : 7 - 7
1234